What science can do AstraZeneca Annual Report and Form 20-F Information 2015 AstraZeneca Annual Report and 20-F Form Information 2015 Marketed Products Respiratory, Inflammation > Symbicort Turbuhaler (budesonide/ > Farxiga/Forxiga (dapagliflozin) is a and Autoimmunity formoterol in a dry powder inhaler) is a selective inhibitor of human sodium- combination of an inhaled corticosteroid glucose co-transporter 2 (SGLT2 inhibitor) > Accolate (zafirlukast) is an oral and a fast onset, long-acting beta2- indicated as an adjunct to diet and leukotriene receptor antagonist for the agonist for the maintenance treatment of exercise to improve glycaemic control in treatment of asthma. asthma and COPD. In asthma, it is also adult patients with Type 2 diabetes. approved for Symbicort Maintenance And > Bricanyl Respules (terbutaline) is a > Kombiglyze XR (saxagliptin and Reliever Therapy (Symbicort SMART). short-acting beta -agonist administered metformin hydrochloride extended 2 Symbicort Turbuhaler is approved in via a nebuliser for acute treatment of release) combines saxagliptin (Onglyza) Europe, Japan and many other countries and extended release metformin asthma and COPD in both children excluding the US. and adults. (metformin XR) in a once-daily tablet for Type 2 diabetes. > Bricanyl Turbuhaler (terbutaline) is a Cardiovascular and > Komboglyze (saxagliptin and metformin short-acting beta2-agonist for the acute Metabolic diseases treatment of bronchial-obstructive hydrochloride) combines saxagliptin symptoms in asthma and COPD. (Onglyza) and metformin immediate Cardiovascular disease release (metformin IR) in a twice-daily > Daliresp (roflumilast) is an oral PDE4 > Atacand1/Atacand HCT/Atacand Plus tablet for Type 2 diabetes. (phosphodiesterase-4) inhibitor for adults (candesartan cilexetil) is an angiotensin II > Onglyza (saxagliptin) is an oral with severe COPD to decrease their antagonist for the 1st line treatment dipeptidyl peptidase 4 (DPP-4) inhibitor number of exacerbations (US only). of hypertension and symptomatic for Type 2 diabetes. > Duaklir Genuair (aclidinium/formoterol heart failure. > Symlin (pramlintide acetate) is an injected in a dry powder inhaler) is a fixed dose > Brilinta/Brilique (ticagrelor) is an amylin analogue for Type 1 and Type 2 combination of a long-acting muscarinic oral antiplatelet for acute coronary diabetes in patients with inadequate antagonist (LAMA) and a long-acting syndromes (ACS). glycaemic control. beta2-adrenergic receptor agonist (LABA) > Crestor 2 (rosuvastatin calcium) is for the maintenance treatment of COPD. > Xigduo (dapagliflozin and metformin a statin for dyslipidaemia and hydrochloride) combines dapagliflozin > Eklira Genuair/Tudorza/Bretaris hypercholesterolemia. (Farxiga/Forxiga), an SGLT2 inhibitor, (aclidinium in a dry powder inhaler) is a > Plendil (felodipine) is a calcium antagonist and metformin IR, in a twice-daily LAMA for the maintenance treatment for hypertension and angina. tablet to improve glycaemic control of COPD. in adult patients with Type 2 diabetes > Seloken/Toprol-XL (metoprolol > Oxis Turbuhaler (formoterol) is a fast who are inadequately controlled by succinate) is a beta-blocker once-daily onset, long-acting beta -agonist for the metformin alone. 2 tablet for control of hypertension, heart treatment of bronchial-obstructive failure and angina. > Xigduo XR (dapagliflozin and metformin symptoms in asthma and COPD. hydrochloride extended-release) > Tenormin3 (atenolol) is a beta-blocker for combines dapagliflozin Farxiga/Forxiga( ), > Pulmicort Turbuhaler/Pulmicort hypertension, angina pectoris and other an SGLT2 inhibitor, and metformin XR, in Flexhaler (budesonide) is an inhaled CV disorders. corticosteroid for maintenance treatment a once-daily tablet to improve glycaemic 4 of asthma. > Zestril (lisinopril dihydrate) is an control in adult patients with Type 2 angiotensin converting enzyme inhibitor diabetes who are inadequately controlled > Pulmicort Respules (budesonide) is for a wide range of CV diseases, including by metformin alone. a corticosteroid, administered via a hypertension. nebuliser, for the treatment of asthma 1 Licensed from Takeda Chemicals Industries Ltd. in both children and adults. 2 Licensed from Shionogi. The extension of the global licence Metabolic disease agreement with Shionogi for Crestor and the modification of > Rhinocort (budesonide) is a nasal steroid the royalty structure became effective 1 January 2014. > Bydureon (exenatide extended-release 3 Divested US rights to Tenormin to Alvogen Pharma US Inc. Additional Information treatment for allergic rhinitis (hay fever), for injectable suspension) is a once- effective 9 January 2015. perennial rhinitis and nasal polyps. 4 Licensed from Merck. Divested US rights to Zestril to weekly injectable glucagon-like peptide-1 Alvogen Pharma US Inc. effective 9 January 2015. > Symbicort pMDI (budesonide/ (GLP-1) receptor agonist available as a formoterol in a pressurised metered-dose single-dose tray or a single-dose pen inhaler) is a combination of an inhaled indicated to improve glycaemic control, corticosteroid and a fast onset, long- in adults with Type 2 diabetes. acting beta2-agonist for maintenance > Byetta (exenatide injection) is a twice- treatment of asthma and COPD, including daily injectable GLP-1 receptor agonist chronic bronchitis and emphysema in the indicated to improve glycaemic control in US, Australia and some other markets. adults with Type 2 diabetes. AstraZeneca Annual Report and Form 20-F Information 2015 203 Additional Information Marketed Products continued Oncology Infection, Neuroscience > Movantik/Moventig (naloxegol) is a and Gastrointestinal once-daily, peripherally-acting mu-opioid receptor antagonist approved for the > Arimidex (anastrozole) is an aromatase Infection treatment of opioid-induced constipation inhibitor used to treat breast cancer. It has (OIC) in adult patients. The indication > Fluenz/FluMist (influenza vaccine been shown to be significantly superior varies by jurisdiction. live, intra-nasal) is an intra-nasal, live, to tamoxifen at preventing breast cancer attenuated, trivalent influenza vaccine. > Naropin (ropivacaine) is a long-acting recurrence during and beyond the local anaesthetic for surgical anaesthesia > Fluenz Tetra/FluMist Quadrivalent1 five-year treatment course. and acute pain management. (influenza vaccine live, intra-nasal) is an > Casodex, Cosudex (bicalutamide) is intra-nasal, live, attenuated, quadrivalent > Seroquel IR (an immediate release an anti-androgen therapy used to treat influenza vaccine. formulation of quetiapine fumarate) is an prostate cancer. A 50mg tablet is used atypical anti-psychotic generally approved > Merrem/Meronem2 (meropenem) is a for advanced prostate cancer; a 150mg for the treatment of schizophrenia and carbapenem anti-bacterial used to treat tablet is used for locally advanced bipolar disorder (mania, depression and serious infections in hospitalised patients. prostate cancer. maintenance). > Synagis3 (palivizumab) is a humanised > Faslodex (fulvestrant) is an injectable > Seroquel XR (an extended release MAb used to prevent serious lower estrogen receptor antagonist. It is used formulation of quetiapine fumarate) respiratory tract disease caused by for the treatment of hormone receptor is generally approved for the treatment respiratory syncytial virus (RSV) in positive advanced breast cancer for of schizophrenia, bipolar disorder, paediatric patients at high risk of post-menopausal women whose disease major depressive disorder and, on acquiring RSV disease. has progressed following treatment with a more limited basis, for generalised prior endocrine therapy. > Zinforo4 (ceftaroline fosamil) is a anxiety disorder. novel injectable cephalosporin used > Iressa (gefitinib) is an epidermal growth > Vimovo1 (naproxen/esomeprazole in community-acquired pneumonia factor receptor-tyrosine kinase inhibitor magnesium) is generally approved for and complicated skin and soft (EGFR-TKI) that acts to block signals symptomatic relief in the treatment of tissue infections. for cancer cell growth and survival in rheumatoid arthritis, osteoarthritis and advanced non-small cell lung cancer 1 ankylosing spondylitis in patients at risk (NSCLC). Daiichi Sankyo holds rights to Fluenz Tetra/FluMist Quadrivalent in Japan. of developing NSAID-associated gastric 2 Licensed from Dainippon Sumitomo Pharmaceuticals Co., > Lynparza (olaparib) is an oral poly Limited. and/or duodenal ulcers. ADP-ribose polymerase (PARP) inhibitor. 3 US rights only. AbbVie holds rights to Synagis outside the US. > Xylocaine (lidocaine) is a short-acting It is approved in the EU for the treatment 4 Licensed from Forest (now a wholly-owned subsidiary of local anaesthetic for topical and of adult patients with platinum-sensitive Allergan). AstraZeneca holds global rights, excluding the regional anaesthesia. relapsed BRCA-mutated (germline US, Canada and Japan. and/or somatic) high-grade serous > Zomig (zolmitriptan) is used for the acute epithelial ovarian, fallopian tube or primary Neuroscience treatment of migraine, plus for the acute peritoneal cancer. It is approved in the US > Diprivan (propofol) is an intravenous treatment of cluster headache in the EU. for the treatment of patients with germline general anaesthetic used to induce and Zomig is available in three formulations: BRCA-mutated advanced ovarian cancer maintain general anaesthesia, intensive oral tablet; orally dispersible tablet; and who have been treated with three